Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AGMB stock hub

AgomAb Therapeutics NV has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AGMBis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

597.4M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AGMB

In the news

Latest news · AGMB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-39.2

P25 -106.6P50 -46.9P75 -3.1

ROIC-23

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AGMB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

157

Groups with data

Currency

EUR

Showing 157 of 157 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002020932
Company name	AgomAb Therapeutics NV
Country	Belgium
Country code	US
Cusip	00860C102
Employees	57.8
Employees Change	23.8%
Employees Change Percent	70
Enterprise value	$462M
Exchange	NASDAQ
Financial currency	EUR
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2026-02-06
Isin	US00860C1027
Last refreshed	2026-05-10
Market cap	$597.4M
Market cap category	Small-Cap
Price	$12.13
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	AGMB
Tags	pharmaceuticals
Website	https://agomab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.23%
FCF yield	-10.22%
P/B ratio	3.89x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-91M
Net Income Growth Years	0%
Profit Per Employee	$-1.6M
ROA	-20.58
ROCE	-43.87
ROE	-39.22
ROIC	-23.03

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$180.5M
Cash	$136.8M
Current Assets	$143M
Current Liabilities	$21.9M
Debt	$1.5M
Debt Equity	$0.01
Equity	$153.7M
Interest Coverage	-987.9
Liabilities	$26.8M
Long Term Assets	$37.5M
Long Term Liabilities	$4.9M
Net Cash	$135.3M
Net Cash By Market Cap	$22.65
Net Debt Equity	$-0.88
Tangible Book Value	$-231.9M
Tangible Book Value Per Share	$-4.71

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.52
Net Working Capital	$-16M
Quick ratio	6.49
Working Capital	$120.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-2,064.5%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	12.11
All Time High	17.45
All Time High Change	-30.5%
All Time High Date	2026-03-03
All Time Low	9
All Time Low Change	34.78%
All Time Low Date	2026-04-09
ATR	1.15
Beta1y	1.61
High	12.75
High52	17.45
High52 Date	2026-03-03
High52ch	-30.5%
Low	11.19
Low52	9
Low52 Date	2026-04-09
Low52ch	34.78%
Ma50ch	0.2%
RSI	54.96
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	-0.6x
Sortino ratio	-0.76
Total Return	-2,064.5%
Tr1m	15.41%
Tr1w	8.4%
Tr3m	-17.2%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	1
Analyst Price Target Top	$32
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-1.79
Operating Income	$-69.6M
Price target	$32
Price Target Change	$164
Price Target Change Top	$164

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	23,411,363%
Float Percent	47.54%
Net Borrowing	-398,602.8
Shares Insiders	0.09%
Shares Institutions	26.33%
Shares Out	49,247,975
Shares Qo Q	0%
Shares Yo Y	2,064.5%
Short Float	1.85%
Short Ratio	2.11
Short Shares	0.88

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-67.3M
Average Volume	151,491.5x
Bv Per Share	-4.02
CAPEX	$-4,696
Ch1m	15.41
Ch1w	8.4
Ch3m	-17.2
Change	6.22%
Change From Open	6.4
Close	11.42
Days Gap	-0.18
Depreciation Amortization	474,864.4
Dollar Volume	1,308,366.1
Earnings Date	2026-04-23
Earnings Time	amc
EBIT	$-69.6M
EBITDA	$-69.1M
EPS	$-168
F Score	2
FCF	$-61M
FCF EV Yield	-13.21x
FCF Per Share	$-1.24
Financing CF	-396,853
Fiscal Year End	December
Founded	2,017
Goodwill	10,156,115.5
Investing CF	-38,750,734
Ipr	-24.19
Iprfo	-17.48
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-23
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-04-23
Ma20	11.16
Ma20ch	8.66%
Net CF	-99,845,016
Next Earnings Date	2026-06-16
Open	11.4
Optionable	No
Position In Range	60.26
Post Close	12.13
Postmarket Change Percent	1.15
Postmarket Price	$12.27
Ppne	1,870,366.8
Price Date	2026-05-08
Relative Volume	0.71x
Share Based Comp	6,287,425
Volume	107,862

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AGMB pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns AGMB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+26.3%

Float: +47.5% of shares outstanding

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AGMB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

55.0

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.60

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AGMB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AGMB stock rating?

AgomAb Therapeutics NV is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AGMB analysis?

The full report lives at /stocks/AGMB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AGMB?

The latest report frames AGMB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AGMB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.